Yesafili Publicly Funded in Ontario: A Beacon of Hope for Retinal Disease PatientsBiocon Biologics has reached a significant milestone with its biosimilar drug Yesafili (aflibercept) now publicly funded in Ontario, Canada’s largest province, for the advanced treatment of retinal diseases. Effective August 29, 2025, this inclusion on the Ontario Drug Benefit (ODB) Formulary ensures that eligible patients can access Yesafili through public health insurance, improving affordability and access to cutting-edge retinal care. The move marks an important development for patients facing vision-threatening retinal disorders and highlights Biocon’s expanding footprint in the North American biosimilars market.
Key Developments in the Announcement
-
Yesafili, a biosimilar to the original biologic drug Eylea (aflibercept), is approved by Health Canada for treating serious retinal diseases, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), macular edema due to retinal vein occlusion (central or branch), and myopic choroidal neovascularization (myopic CNV).
-
It is offered in two presentations: vial and prefilled syringe, both at a dosage of 2 mg/0.05 mL, facilitating flexible administration options.
-
The listing on Ontario’s ODB formulary, effective from late August 2025, allows public funding coverage, thereby removing financial barriers for many patients in need.
-
Wet AMD and related retinal diseases affect over 2 million Canadians and represent a leading cause of irreversible vision loss globally, imposing heavy burdens on patients, caregivers, and healthcare systems.
-
Ramy Ayad, Head of Canada at Biocon Biologics, emphasized that this is Canada’s first biosimilar to Eylea approved and funded publicly, underscoring the company’s mission to improve access to biologics at affordable prices, delivering savings to the healthcare system while expanding patient access.
Understanding Yesafili: A Biosimilar That Matches the Original
Yesafili’s approval was backed by extensive analytical, preclinical, and clinical evidence demonstrating its high similarity to Eylea. The pivotal Phase 3 INSIGHT study compared Yesafili directly with Eylea in patients with diabetic macular edema, showing no clinically meaningful differences regarding pharmacokinetics, safety, efficacy, or immunogenicity. In essence, patients receiving Yesafili can expect the same therapeutic benefits with a biosimilar that meets stringent regulatory standards.
Mechanism of Action and Indications
-
Yesafili functions as a vascular endothelial growth factor (VEGF) inhibitor, blocking abnormal blood vessel growth and leaking in the retina which contribute to vision loss.
-
Indicated for neovascular (wet) AMD, visual impairment due to macular edema secondary to central and branch retinal vein occlusion (CRVO/BRVO), diabetic macular edema (DME), and myopic choroidal neovascularization.
-
This range of indications addresses some of the most common and impactful retinal diseases affecting aging and diabetic populations globally.
Impact on Patients and Healthcare System
By securing public funding for Yesafili in Ontario, the largest healthcare market within Canada, Biocon Biologics is paving the way for broader patient access to an advanced treatment option that is more affordable. This helps alleviate out-of-pocket expenses for patients and caregivers, potentially improving adherence and outcomes in a population suffering debilitating eye diseases. Moreover, public funding of biosimilars like Yesafili can generate substantial cost savings for healthcare providers by offering effective alternatives to expensive originator biologics.
Strategic Implications for Biocon Biologics
This approval and public funding represent a major commercial opportunity for Biocon Biologics in Canada and strengthen its position in the global biosimilars landscape. Yesafili is now the seventh biosimilar launched by Biocon Biologics in the Canadian market, reflecting the company’s strategic focus on expanding biosimilar access and sustainable healthcare solutions. It also sets the stage for future launches in North America, including the planned U.S. market entry potentially as early as 2026.
Closing Thoughts
Biocon Biologics’ success with Yesafili’s public funding in Ontario underscores a transformative shift in the management of retinal diseases. As biosimilars increasingly gain regulatory and payer acceptance, they provide cost-effective treatment alternatives without compromising quality or efficacy. For patients grappling with vision loss risks due to retinal conditions, this development holds the promise of improved accessibility and enhanced health outcomes—signaling a win-win for healthcare systems, patients, and innovators alike.
Source: Biocon Biologics Press Release
